NIDA

Nora Volkow, director of the National Institute on Drug Abuse (NIDA), has raised concerns over the cannabis industry’s marketing strategies, drawing parallels with tactics used by the alcohol and tobacco industries. In a blog post published last week, Volkow highlighted that older adults...

Nora Volkow, director of the National Institute on Drug Abuse (NIDA), has stressed the urgent need to overhaul America’s approach to drug addiction. In a recent opinion piece published in STAT and republished on NIDA’s website, Volkow criticized the prevailing notion that incarcerating...

"Tremendous Excitement" Around Psychedelic Medicine, Says Top Federal Drug Official There is "tremendous excitement" about the therapeutic potential of psychedelics, says National Institute on Drug Abuse (NIDA) Director Nora Volkow. However, this top federal drug official emphasized that while...

People prescribed Ozempic or Wegovy are less likely to develop a cannabis use disorder or relapse from the condition than those who take other diabetes or obesity medications, reported the NewScientist on Thursday. As brand names for the compound semaglutide, Ozempic and Wegovy are said to reduce...

A Canadian study, recently published in the journal Archives of Public Health, has found that high school students are reporting decreased access to cannabis following its legalization for adults in 2018. The research, conducted in British Columbia, Alberta, Ontario and Quebec with data collected...

A Monitoring the Future (MTF) survey, which studies teen drug habits, delivered a surprise on Wednesday: teenage cannabis use has remained stable across all age groups, even as more states embrace legal weed for adults. The survey, conducted by the University of Michigan found that...

Published this July and funded by partners SABI Mind, MAPS PBC and Psygen, a Canadian survey of 2,384 participants showed that over 30% of Canadians use natural psychedelics for self-medicating purposes, yet few are closely followed by their healthcare providers (HCP)...

Cannabis and psychedelics consumption continued on a long-term upward trajectory to reach all-time highs in 2022, according to a Monitoring the Future (MTF) study. Although teenage marijuana use showed a year-over-year decline per last summer’s survey.  Past-year...

With more and more states and countries embracing cannabis whether for medical or recreational purposes, it could be assumed that the number of people dependent on it would also increase. Even now, the Centers for Disease Control and Prevention warns that estimates show every 3 in 10 people...

Researchers in California have come up with a scientific explanation as to why cannabis users tend to be thinner and less diabetes-prone despite the munchies. The new facts should be a cautionary tale for teenagers to hold off before lighting up.  According to a new study ...

As several states advance measures relating to the lawful use of psychedelic medicines and with Congressmembers aiming to do their part at the federal level, a key sign could anticipate further movement in Washington D.C.  Caitlin Oprysko wrote in POLITICO that in recent years, more...

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), said that regulating cannabis products is "crucial," to address the pace of states' adoption of both medical and recreational use of cannabis. "I think that is crucial because, as you know, the majority of...

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), said that psychedelic substances have promising potential for therapeutic uses, particularly for treating severe depression, post-traumatic stress disorder (PTSD) and addiction. Accelerating Research At a...

Young men with cannabis use disorder, or excessive dependency on marijuana consumption, are at higher risk of developing schizophrenia, according to a study led by researchers at the Mental Health Services in the Capital Region of Denmark and the National Institute on Drug Abuse (NIDA) at...

Department of Health and Human Services (HHS) Secretary Xavier Becerra said earlier this month that the agency plans to review the status of cannabis as a Schedule I drug following President Joe Biden's historic announcement that he will pardon federal cannabis possession convictions,...